𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The relationship between extrapyramidal signs and cognitive function in patients with moderate to severe Alzheimer's disease

✍ Scribed by Dr. Marcus Richards; Declan McLoughlin; Raymond Levy

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
478 KB
Volume
10
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The relationship between non-cognitive s
The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease
✍ W. Y. W. Mok; L. W. Chu; C. P. Chung; N. Y. Chan; S. L. Hui 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract ## Objective Cognitive impairment is an important determinant for functional impairment in Alzheimer's disease. The role of non‐cognitive symptom is uncertain. The objective of this study was to investigate the role of non‐cognitive symptoms as predictive factors for functional outcome

Tolerability of switching from donepezil
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 1 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving

Improvement in behavioural symptoms in p
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
✍ S. Gauthier; H. Loft; J. Cummings 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## Introduction Behavioural disturbances are a common and distressing aspect of Alzheimer's disease (AD). This pooled analysis evaluated the specific benefits of memantine on behavioural disturbances in patients with moderate to severe AD. ## Methods Data were pooled from six 24/28‐w

The validity and reliability of the Turk
The validity and reliability of the Turkish versii̇on of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects
✍ H. Mavioglu; M. Gedizlioglu; S. Akyel; T. Aslaner; E. Eser 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## Abstract ## Objectives The cognitive subscale of the Alzheimer's Disease Assesment Scale (ADAS‐Cog) is the most widely used test in clinical trials dealing with Alzheimer's disease (AD). The aim of this study was to investigate the validity and reliability of the Turkish version of ADAS‐Cog. #

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Effects of memantine on cognition in pat
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
✍ Patrizia Mecocci; Anna Bladström; Karina Stender 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 2 views

## Abstract ## Objectives The post‐hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS‐cog single‐items or SIB subscales for patients with moderate to severe AD. ## Methods Data from six multicentre, randomised, placebo‐controlled, parallel‐group, double‐blind